Cauldron Ferm Raises $13.25 Million to Scale Continuous Hyper-Fermentation Platform Beyond 10,000-Liter Demonstration
Australian biomanufacturing startup Cauldron Ferm has closed a $13.25 million Series A2 round to expand its continuous hyper-fermentation platform, which it claims reduces unit costs by up to 50 percent and capital expenditure by 45 percent compared to conventional batch processes.
Cauldron Ferm, an Australian biomanufacturing startup that has developed a continuous fermentation process it calls hyper-fermentation, announced a $13.25 million Series A2 funding round led by Main Sequence Ventures, with participation from Horizons Ventures, SOSV, and NGS Super. The round brings the company’s total funding to $26 million and will finance the expansion of its fermentation platform from a 30,000-liter demonstration facility in New South Wales to a planned 500,000-liter commercial plant in Mackay, Queensland.
The company has also been named to Fast Company’s 2026 list of most innovative companies and was previously selected for the World Economic Forum’s Technology Pioneers program.
From batch to continuous
Conventional industrial fermentation operates in batches: a bioreactor is filled, sterilized, seeded with microorganisms, and run until productivity declines, at which point the vessel must be cleaned and restarted. The process is capital-intensive and inefficient, with significant downtime between production cycles.
Cauldron’s approach keeps microbes in a continuously productive state, turning them into what the company describes as nonstop assembly lines. The technology uses proprietary bioreactor design and growth medium formulations to sustain microbial productivity around the clock, enabling more frequent and larger-volume harvests without the sterilization cycles that interrupt batch processes.
The company claims this delivers measurable cost advantages: up to 50 percent reduction in net unit costs, 20 percent more output, and 45 percent less capital expenditure compared to fed-batch methods. The process also uses less electricity and water per unit of product.
Cauldron is the first company approved to manufacture precision-fermented protein at 10,000-liter scale in Australia, having received a DIR200 license in 2024 from the national gene technology regulator for its Pichia pastoris strain. The Mackay facility, once completed, would target annual output exceeding 1,000 tonnes across food ingredients, nutrition, materials, beauty products, chemicals, and biofuels.
A four-decade origin story
The technology has roots stretching back 40 years. David and Polly McLennan spent decades refining continuous fermentation techniques for microbial protein production. Michele Stansfield, who joined the McLennans’ operation in 2012, recognized the broader commercial potential and transformed the business into a venture-backed startup. Stansfield raised a seed round and acquired the intellectual property, physical, and business assets, eventually founding Cauldron Ferm in 2022.
The company had previously raised $6.5 million in 2024. The new Series A2 round was led by Main Sequence Ventures, the deep-tech venture arm backed by Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO). Horizons Ventures, the investment firm of Hong Kong businessman Li Ka-shing, also participated.
The infrastructure bottleneck
Cauldron’s funding arrives amid a broader reckoning over fermentation infrastructure. The precision fermentation sector has attracted billions in investment over the past five years, but the industry faces a persistent gap between laboratory-scale proof of concept and commercial-scale production. Building a fermentation facility capable of producing ingredients at competitive prices can cost hundreds of millions of dollars in capital expenditure, a barrier that has slowed many startups.
Governments have begun responding. In the United States, the Biden administration awarded $51 million to the Illinois Fermentation and Agriculture Biomanufacturing Tech Hub as part of a broader $504 million investment across 12 regional technology hubs. The Illinois hub, which has since attracted a combined $680 million in public-private investment, is building shared fermentation infrastructure with partners including ADM and Primient to reduce the capital burden on emerging biotech companies.
Cauldron’s pitch is that continuous fermentation can address the cost side of this equation directly. By reducing capital expenditure requirements by nearly half and improving throughput from existing equipment, the technology could lower the threshold for commercially viable biomanufacturing. CEO Michele Stansfield stated that “bioprocess innovation is how we get there” when discussing the path to competitive industrial biomanufacturing.
Whether the approach scales as promised from 10,000-liter demonstration to 500,000-liter commercial production will be the critical test. The company’s clients are already commercializing bio-based food ingredients, chemicals, and nutraceuticals using the platform, but the jump to the Mackay facility represents a 50-fold increase in capacity.